Tagrisso
Phase 2Small molecule
Tagrisso is one of 40 small molecule programs targeting Osimertinib. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
43 competitors in Advanced
#DrugCompanyPhaseTrials
1Remodulin
United TherapeuticsPhase 3
Lenvima
EisaiPhase 2
Fludara
SanofiPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Keytruda
Merck & Co.Phase 2
Tecentriq
RochePhase 2
Cabometyx
Bristol-Myers SquibbPhase 2
Beyfortus
BeiGenePhase 2
Nolvadex
AstraZenecaPhase 2
Avastin
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osimertinib1 trial
Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tagrisso. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSuzhou Genhouse Bio Co., Ltd.